*Organization & Developments: AbbVie (Archives 2019-2021)

Parents

2019: AbbVie And Allergan - Take Advantage Of AbbVie's Share Price Drop_seekingalpha.com
2019: AbbVie Goes All-In On Wearables And Digital Technologies
2019: AbbVie Looks To Tackle Humira Biosimilar Issue With 2 New Powerhouse Drugs_seekingalpha.com
2019: AbbVie: Not A Swan, But A Steal At Its Current Price_seekingalpha.com
2019: AbbVie: This Dividend Aristocrat Offers Double-Digit Total Return Potentialseekingalpha.com
2019: AbbVie: Value Trap? Maybe, But Here's Why It Can Revive_seekingalpha.com
2020: AbbVie cuts Editas CRISPR pact it inherited from Allergan
2020: AbbVie eyes cancer, immunology in latest protein degradation pact, handing Frontier Medicines $55M upfront
2020: AbbVie: A Post Allergan Powerhouse
2020: AbbVie: Another Opportunity
2020: Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101
2020: Editas Medicine initiated with a Buy at SunTrust EDIT;ABBV
2020: Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead
2021: Dividend Diligence On AbbVie With Seeking Alpha